SEC Form 4 · accession 0001665124-26-000013
Taysha Gene Therapies, Inc. · TSHA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sukumar Nagendran
Officer — President and Head of R&D · Director
Period of report
Jul 10, 2026
Accepted (ET)
Jul 10, 2026 · 6:54 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001806310
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 10, 2026 | S | 200,000 | $6.24 | D | 936,410 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.99 to $6.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.